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Introduction
Iron Deficiency Anemia (IDA) is a major nutritional problem globally which is especially true in developing
countries like India. IDA is associated with worsened quality of life, impaired physical & cognitive
performance. Even though treatment patterns are simple & effective, there is a high prevalence of IDA. The
reason for this is partly due to non-compliance of the patients & partly due to ineffective/incomplete treatment
by physicians.[4] Due to the risks associated with blood transfusions, alternative treatments of anemia in the
critically ill are being explored.[5]

Objectives
To assess the pattern, risk factors and treatment of IDA in adult and pediatric population in a tertiary care
hospital in South India.

Methodology
A retrospective observational study conducted in Kasturba Hospital on patients with Iron Deficiency Anemia
admitted during the year 2017 after ethical committee approval. Medical records of these patients were
reviewed and relevant data was recorded in the CRF. Demographic information of patients, family and social
history, risk factors of each patient, and their treatment pattern were estimated and recorded. Collected Data
was documented and analyzed using SPSS version 20.

Results
A total of 894 patients’ data diagnosed as IDA in the year 2017 was included for the study, out of which
401(44.8%) were pediatric and 493 (55.1%) were adult patients. It was observed that the highest distributed
risk factor in pediatrics was age below 2 years (54.6%) and in adults it was Female gender (55.9%). It was
also seen that pallor (pediatric- 41.39% and adults-49.08%) was the highest observed clinical manifestation
in both the groups. The standard treatment for IDA was provided to 30.1% pediatric patients and 40.3%
adult patients.

Conclusion
Study concludes that it helps in identifying the various risk factors and clinical manifestation of IDA which
will in turn help in prevention of the disease by early assessment of the disease based on these factors. It also
gives us an idea of the changes to be made in the treatment pattern and/or to provide counselling to patients
regarding medication and food habits for better outcome of the disease.

8

INTRODUCTION

9

1. Introduction
The WHO defines Anemia as a condition in which the number of red blood cells or their oxygen-carrying
capacity is insufficient to meet physiological needs, which vary by age, sex, altitude, smoking, and pregnancy
status.

[6]

According to WHO, the normal haemoglobin values for children (6-59 months of age) is 11mg/dL

or higher, for children (5-11 months of age) is 11.5mg/dL or higher, children (12-14 years of age) is 12mg/dL
or higher, for women (15 years and above) is 12mg/dL or higher and for men ( 15years and above) is 13mg/dL
or higher.

[9,10]

Anemia is one of the most common health problem in India,

[7]

. Out of the various different

kinds of anemia Iron deficiency anemia (IDA) is thought to be the most common cause of anaemia globally
[8]

which is reduced Iron concentration in the body[11], although other conditions, such as folate, vitamin B12

and vitamin A deficiencies, chronic inflammation, parasitic infections and inherited disorders can all cause
anemia. Majority of the patients with IDA have severe IDA (58%), followed by moderate IDA (36%). [8] In
its severe form, it is associated with fatigue, weakness, dizziness, drowsiness and various other clinical
manifestations. [6] The normal TIBC levels are 250-400 mcg/dl and the normal ferritin levels for age group 218 years are 7-140ng/ml and for 18-49 years are 15-200ng/dl for males and 12-150ng/dl for females. The
TIBC value above the normal range and ferritin value below the normal range causes IDA. [13]

The risk factors for anemia include Social determinants- race/ethnicity, poverty, food in- security;
behavioural determinants- Tobacco use, Nutritional intake, Body mass index, physical activity; Reproductive
history- Years since menarche, usage of oral/IV contraception, Older women only (live births, time on oral
contraceptive) and various others. For women with risk factors like menstrual or other blood loss, low iron
intake, previous diagnosis of anemia are recommended for annual objective screening while adolescents can't
quantify blood loss or iron intake hence, guidelines do not advise how many years after menarche to start
screening. It was found that adolescent risk factors are not the same as for older reproductive age women. [3]
Worm infestation is also one of the major problems in India for causing IDA, especially for females over
males. [29]

The high risk groups for anemia include pregnant women and children. [6] The prevalence of anemia in adults
was found to be 53% and about 204997 children aged between 6-59 months were diagnosed with anemia [1]
Most of the patients who suffer from anemia are female (71%) and are usually more than 15 years of age.
This could be attributed to the low nutrition intake in the females and menstrual blood loss that occurs every
month. [1]

10

Need for the Study

According to NFHS-4 (National Family Health Survey), 2015-16, the prevalence of anemia in adults was
found to be 53% and about 204997 children aged between 6-59 months were diagnosed with anemia. [1] Study
by Rakesh et al. stated that the prevalence of Anemia is not known in the South Indian population. There are
many reports and surveys that cannot be combined, due to non-uniform haemoglobin estimation methods. [2]

Shekhar et al. studied the risk factors for anemia which included Social determinants- race/ethnicity, poverty,
food insecurity; behavioral determinants- Tobacco use, Nutritional intake, Body mass index, physical
activity; Reproductive history- Years since menarche, usage of oral/IV contraception, Older women only
(live births, time on oral contraceptive) and various others.[3]

In Kasturba Hospital, Manipal which is a 2000 bedded tertiary care hospital with various specialties; there
were more than 2000 different types of anemic patients admitted per year in Medicine and Pediatric wards.
hence, there is a need to assess the risk factors in this population. Hence, we are carrying out this study to
compare the prevalence of anemia in adult and pediatric population in a tertiary care hospital in South India
along with the treatment pattern, risk factors and clinical manifestations associated with IDA.
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2.OBJECTIVES
•

To assess the pattern, risk factors and treatment of Iron Deficiency Anemia in adult and pediatric
population in a tertiary care hospital in South India.

•

To study the demographic and clinical characteristics of IDA in patients.

•

To assess the severity of IDA.

•

To compare various study parameters in adult and pediatric population with respect to IDA.

13
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3. METHODOLOGY
3.1 Study Site: Kasturba Hospital, Manipal.
3.2 Study Design: Retrospective Observational Study
3.3. Study Period: August 2018 to March 2019
3.4 Ethical Clearance: Obtained from the Institutional Ethics Committee, Kasturba Hospital, Manipal
MAHE. (Appendix 1) (471/2018)
3.5 Sample Size: A total number of 974 ( 801-IDA | 83-IDA+MEGALOBLASTIC ANEMIA) subjects
diagnosed with IDA in the year 2017 were included in the study.
3.6 Study Criteria:
Inclusion Criteria: All in-patients with final diagnosis of IDA admitted in Kasturba Hospital, Manipal
during January 2017-December 2017
Exclusion Criteria: Patient files with incomplete data and/or other types of Anemia.
3.7 Sources for Data Collection:
Patient Case Records which contained the following data:
-Patient Demographics
-Patient History notes
-Patient risk factors
-Laboratory tests
-Drug treatment charts
-Outcomes
-Discharge Medications and follow up.

3.8 Materials Used: Case Record Form (CRF). (Appendix 2)
15

3.9 Operation Modality:
All patients satisfying the inclusion criteria admitted in the year 2017 in a tertiary care hospital with the
final diagnosis as IDA were included in the study. The medical records of these patients were obtained from
the medical record department (MRD). The data from the patients’ file were reviewed and documented in
the CRF individually for each patient. The data was analysed using SPSS 20 and the distribution of all the
particulars were checked in pediatric (0-18 years) and adult ( >18 years) patients.

Patients with
Anemia
admitted in
Inclusion criteria
Exclusion criteria

IDA

Megalobalstic
Anemia

Megalobalstic
Anemia + IDA

Data entered into
CRF

Data entered into
SPSS and
analyzed

Outcome
assessed for
pediatrics

Outcome
assessed for
adults
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3.10 Collection of Data:
The medical records of all IDA patients were reviewed and the details of the patient were entered in a case
record form. Demographic details like age, gender, occupation and social history were noted. Information
regarding the presence of any risk factors or chronic illness, medical history and type of admission were
retrieved from the files on a structured CRF. The various Laboratory values were noted down and the
severity classified based on the WHO classification ( Table 1) .

Table 1; Haemoglobin levels to diagnose anaemia at sea level (mg/dl) .[9,10]
Population

Non-anemia

Mild

Moderate

severe

Children 6-59
months of age

11 or higher

10-10.9

7-9.9

7 or lower

Children 5-11
months of age

11.5 or higher

11-11.4

8-10.9

8 or lower

Children 12-14
years of age

12 or higher

11-11.9

8-10.9

8 or lower

Non-pregnant
women (15 years
of age and above)

12 or higher

11-11.9

8-10.9

8 or lower

Pregnant women

11 or higher

10-10.9

7-9.9

7 or lower

Men (15 years and
above)

13 or higher

11.12.9

8-10.9

8 or lower

3. 11 Data Analysis and Statistics:
The obtained data from the medical records of patients with IDA were analysed for various parameters like
demographic data, gender ratio, risk factor distribution, clinical manifestation, prescription pattern,
discharge medications, laboratory values, outcomes and severity for pediatrics (age below 18 years) and
adults (age above 18 years), etc. using SPSS version 20. The results of pediatrics and adults were compared
and represented as descriptive statistics.
The various risk factors for IDA were assessed as follows:
Age below 2 years and above 60 years [20][21], Child bearing age [19], Female gender [1], Low socio economic
group (occupation, geographical area) , Alcohol, Smoking, Chronic Disease, Pregnancy, History of blood
loss, History of taking NSAID or Aspirin, Diet, Worm infestation, Haemorrhoids, Nose Bleeding,
Postpartum Haemorrhage [13]
17

The various clinical manifestations for IDA were assessed as follows:
Chest Pain, Pallor, Fatigue, Dizziness, Irritability, Weakness, Palpitations, vertigo, Tingling, Shortness of
breath, Decreased exercise tolerance and tachycardia [13]

18
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4. RESULTS
A total of 995 patients’ data were collected during the study period out of which 811 were diagnosed with
IDA, 101 were diagnosed with Megaloblastic anemia and 83 were diagnosed as IDA and Megaloblastic
anemia. In this study we are focusing on the patients diagnosed with IDA, that is 894 patients.

4. 1 Demographic characteristics of patients with IDA
Total of 894 patients were admitted and diagnosed with IDA in the year 2017. Among them 401 were
pediatric and 493were adult patients.
Gender wise distribution:
Out of 401 pediatric patients 229 (57.1%) patients were male and 172 (42.8%) were female and out of 493
(55.1%) adult patients 213 (43.2%) were male and 280 (56.8%) were female which is shown in Table 2.
Food Habit wise distribution:
Amongst 401 pediatric patients 109 (26.1%) were vegetarians, 34 (8.4%) were non vegetarians and the data
was not available for 258 (64.3%) patients and out of 493 adult patients 71 (14.3%) were vegetarians, 180
(36.4%) were non vegetarians and the data was not available for 242 (48.9%) patients as shown in table 2.
Geographical area wise distribution:
From the 401 pediatric patients 348 (86.7%) were from rural areas and 53 (13.2%) were from urban areas
and among 493 (85.6%) adult patients 423 (85.6%) were from rural areas and 70 (14.1%) were from urban
areas.

Table 2; General characteristics of patients with IDA
GENDER-Number of patients (%)

FOOD HABITS- Number of patients
(%)

MALE

Female

VEG

NON
VEG

PEDIATRIC
(N=401)

229 (57.1)

172 (42.8)

109 (26.1) 34 ( 8.4)

258 (64.3)

ADULTS
(N=493)

213 (43.2)

280 (56.8)

71 (14.3)

242 (48.9)

18 (36.4)

NOT
MENTIONED
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Age group wise distribution in IDA patients:
Depicted in Table 3 is the distribution of the various kinds of anemia in different age groups. In pediatrics
Infants (28 days to 12 months) are in majority who have IDA and in adults young adults (19-30 years) are in
majority who have IDA.

Table 3; Age group wise distribution in IDA patients.
Age group
Infancy (28 days to 12 months )

No. of Patients (%)
(N=894)
142 (35.4)

Toddler (13months-2 years)
Early Childhood (2-5years)
Middle childhood (6-11 years)
Early Adolescence (12-18 years)
Young adult (19-30 years)
Middle aged adults (31-59 years)
Geriatrics (>60 years)

87 (21.6)
81 (20.1)
52 (12.1)
39 (9.7)
207 (41.9)
158 (32)
128 (25.9)

4.2 Distribution of Various Risk Factors for IDA in Adults and Pediatrics
The various risk factors for Anemia based on studies include Age below 2 years and above 60 years, female
gender, occupation, child bearing age ( 15-44 years) , alcohol, smoking, chronic disease, low absorption in
IDA, pregnancy, GI Bleeding, history of blood loss, history of taking aspirin or NSAID, food habits-veg,
place-rural, worm infestation, hemorrhoids, nose bleeding, postpartum hemorrhage and various drug use.
Risk factor distribution in pediatric IDA patients:
Out of 401 pediatric patients 219 (54.6%) patients were below the age of 2 years, 164 (40.9%) patients were
female, 19 (4.7%) patients were of the child bearing age, 5 (1.2%) pediatric patients had a history of blood
loss, 2 (0.5%) patients had GI bleeding, 1 (0.2%) patient had a family history of IDA, 1 (0.2%) patient had
chronic diseases, and 1 (0.2%) patient used methotrexate which is associated with increased risk of Iron
Deficiency Anemia.
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Risk factor distribution in adult IDA patients:
Among 494 adults , 276 (55.9%) patients were female, 188 (38.1%) patients were of the child bearing age,
128 (25.9%) patients were above the age of 60 years, 103 (20.8%%) patients had chronic diseases, 42
(8.5%) adult patients had a history of blood loss, 29 (5.8%) adult patients had a history of alcohol use, 18
(3.6%) adult patients had a history of smoking, 16 (3.2%) adult patients had a history or using NSAID/
aspirin. There were 13 (2.6%) pregnant women. 14 (2.8%) adult patient had a family history of IDA, 10
(2%) adult patients had GI bleeding, 5 (1%) adult patients used a drug associated with anemia which were
Sulfasalazine, methotrexate and corticosteroid, 4 (0.8%) adult patients had an occupation which were risk
factors to anemia, those being-farmer, field worker and fishermen, 3 (0.6%) adult patients had low
absorption in IDA, 3 (0.6%) adult patients had worm infestation and 1 (0.2%) adult patient had a previous
medical history of IDA which is represented in figure 1.
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AGE CATEGORY
PEDIATRIC-401

ADULT-493

Figure 1; Distribution of various risk factors in Adults and Pediatrics

4.3 Presence of Clinical Manifestations of IDA in patients
Among 401 pediatric patients 194 (48.4%) patients had clinical manifestations of IDA present and
207(51.6%) patients had no clinical manifestations present.
Out of 493 adult patients 348 (70.5%) patients had clinical manifestations present and 145 (29.4%) patients
had no clinical manifestations present.
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Figure 2; Presence of clinical manifestations in pediatrics

Figure 3; Presence of clinical manifestations in
adults

4.4 Distribution of Clinical Manifestations
The various clinical manifestations associated with anemia are chest pain, fatigue, dizziness, irritability,
weakness, palpitations, vertigo, tingling, shortness of breath, decreased exercise tolerance, tachycardia and
pallor.
Distribution of clinical manifestations in pediatric patients:
Out of 401 pediatric patients 166 (41.39%) patients had pallor, 12 (2.9%) patients felt fatigued, 9 (2.24%)
patients were weak, 8 (1.9%) patients had shortness of breath, 4 (0.9%) patients were irritable, 3 (0.7%)
patients were dizzy, 1 (0.2%) patient had palpitation, 1 (0.2%) patient had chest pain and 1 (0.2%) patient
had tachycardia which is shown in figure 4.
Distribution of clinical manifestations in adult patients:
Out of 493 adult patients 242 (49.08%) patients had pallor, 96 (19.47%) patients felt fatigued ,80 (16.2%)
patients had shortness of breath, 52 (10.54%) patients were weak, 24 (4.86%) patient had chest pain, 10
(2.01%) patients had decreased exercise tolerance, 5 (1.01%) patient had palpitation, 5 (1.01%) patients had
tingling, 4 (0.81%) patients were irritable, 3 (0.6%) patients were dizzy, 2 (0.4%) patients had vertigo and 1
(0.2%) patient had tachycardia which is also shown in figure 4.
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Figure 4; Distribution of clinical manifestations in pediatrics and adults.

4.5 Severity
The severity was categorised based on the WHO classification depicted in Table 1 and in this study the
laboratory values were not assessed for 5 (1.2%) pediatric patients and 11 (2.2%) adult patients due to
which their severity could not be classified.
Classification of severity of anemia in pediatric patients:
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Out of 401 pediatric patients 77 (19.2%) had mild anemia, 269 (67.1%) had moderate anemia and 31 (7.7%)
had severe anemia. The values were normal for 19 (4.7%) pediatric patients.
Classification of severity of anemia in adult patients:
and of 493 adult patients 61 (12.4%) patients had mild anemia, 243 (49.3%) had moderate anemia and 167
(33.9%) patients had severe anemia. The value were normal for 11(2.2%) adult patients.

Figure 5; Severity in Pediatrics

Figure 6; Severity in Adults

4.6 Outcome
The outcome of the treatment varied for adults and pediatrics as shown in figure 7.
Outcome of therapy for pediatric patients:
Out of 401 pediatric patients, 93 (22.3%) patients’ laboratory values and condition improved after treatment,
66 (17.2%) patients’ values did not improved and data was not available for 242 (60.4%) patients.
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Outcome of therapy for adult patients:
Out of 478 adult patients, 246 (49.8%) patients’ laboratory values and condition improved after treatment,
86 (17.4%) patients’ values did not improve and data was not available for 146 (29.6%) patients.

Figure 7; Outcome of treatment

4.7 Comparison of Laboratory values before and after treatment.
Although the data was not available for all the patients, in table 6 and table 7 the laboratory values for
pediatrics and adults are depicted during admission and follow up respectively.
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Table 4; Laboratory parameters on admission and during discharge in pediatric patients.
PEDIATRIC (N=401)
DURING STAY
HB (g/dl)
MCV (fl)
MCHC (g/dl)
MCH (pg)
PCV (%)
TIBC (mcg/dl)
RBC (cells/µL)
FERRITIN (ng/mL)
VITAMIN B12 (pg/ml)
FOLIC ACID (µg)
RDW (%)
IRON (mcg/dl)
TRANSFERRIN
(mg/dL)
INTRINSIC FACTOR
(AU/mL)
MMA (mmol/L)
HOMOCYSTEINE
<(mg/dl)

DURING FOLLOW UP

MEAN ± STANDARD DEVIATION
10.07±1.71
10.07±4.81
68.40±34.53
73.60±54.07
34.30±25.11
33.89±24.27
22.19±3.98
23.20±7.36
31.10±14.52
30.60±5.21
183.35±192.15
34.7±0
6
6
4.94*10 ±3.83*10
4.91*106 ±2.74 *106
55.04±76.28
0
569.30±603.28
0
15.50±.4242
0
18.07±9.35
18.9±5.73
32.90±48.60
0
0
0
0

0

0
0

0
0

Table 5 ; Laboratory parameters on admission and during discharge in adults
ADULT (N=493)
DURING STAY
HB (g/dl)
MCV (fl)
MCHC (g/dl)
MCH (pg)
PCV (%)
TIBC (mcg/dl)
RBC (cells/µL)
FERRITIN (ng/mL)
VITAMIN B12 (pg/ml)
FOLIC ACID (µg)
RDW (%)
IRON (mcg/dl)
TRANSFERRIN (mg/dL)
INTRINSIC FACTOR
(AU/mL)
MMA (mmol/L)
HOMOCYSTEINE <(mg/dl)

DURING FOLLOW UP
MEAN ± STANDARD DEVIATION
9.46±1.98
8.42±2.37
74.57±41.97
76.40±38.26
31.21 ±2.50
33.4±23.74
23.57±12.7
25.25±15.64
27.72±17.97
30.24±16.70
334.59±166.8
232.42±147.70
3.87*106 ±1.74 *106
4.28*106 ±2.52*106
112.76±262.98
124.40±162.98
701.11±728.49
1163.6±767.69
11.60±8.03
0
19.67±11.1
21.6±7.42
38.02±55.17
83.50±75.05
0
0
0
0
0
0

0
0
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4. 8 Treatment pattern during hospital stay and discharge
The treatment pattern during hospital stay and discharge was recorded. Although not all the patients were
given treatment during hospital stay and discharge.
Treatment pattern for IDA in pediatric patients:
Out of 401 pediatric patients 121 (30.1%) patients received treatment during hospital stay and 280 (69.8%)
patients did not receive treatment during hospital stay, the details of which is represented in table 6.
Treatment pattern for IDA in adult patients:
493 adult patients with IDA 199 (40.3%) patients received treatment and 194 (39.3%) patients did not
receive treatment during hospital stay, the details of which is represented in table 7.

Table 6; Pattern of treatment during hospital stay for pediatrics.
DRUG

FREQUENCY

FERROUS ASCORBATE+FOLIC ACID
100MG+1.1MG
IRON HYDROXIDE+FOLIC
ACID+VIT B12
25MG+500MCG+5MCG
IRON+FOLIC ACID+ZINC SULPHATE
100MG+1.5MG+22.5MG
CYANOCOBALAMIN+ELEMENTAL
COPPER+ELEMENTAL MANGANESE
+FERROUS AMMONIUM CITRATE
+FOLIC ACID
7.5MCG+3MCG+30MCG+160MG+0.5
MG
FERROUS FUMARATE
+MULTIVITAMINS
30 MG

ONCE A DAY

NO. OF
PATIENTS (%)
(N=401)
6 (1.4)

ONCE A DAY
TWICE A DAY
NA
ONCE A DAY

293 (73)
6 (1.4)
17 (4.2)
1 (0.2)

ONCE A DAY

1 (0.2)

NA

1 (0.2)
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INJ IRON SUCROSE
100 MG
NO ANEMIC DRUG

NA

3 (0.7)

NA

280 (69.8)

Table 7; Pattern of treatment on discharge for pediatrics

DRUG

PEDIATRIC
FREQUENCY

FERROUS ASCORBATE+FOLIC
ACID
100MG+1.1MG
IRON HYDROXIDE+FOLIC
ACID+VITB12
25MG+500MCG+5MCG
CYANOCOBALAMIN+ELEMENTA
L COPPER+ELEMENTAL
MANGANESE +FERROUS
AMMONIUM CITRATE +FOLIC
ACID
7.5MCG+3MCG+30MCG+160MG+0
.5MG
NO ANEMIC DRUG

ONCE A DAY

NO . OF
PATIENTS (%)
(N=401)
6 (1.4)

ONCE A DAY

297 (74)

TWICE A
DAY
NA
1-0-1

2 (0.4)
17 (4.2)
1 (0.2)

NA

78 (19.4)

Table 8; Pattern of treatment during hospital stay for adults
DRUGS

FREQUENCY

FERROUS ASCORBATE+FOLIC
ACID
100MG+1.1MG

ONCE A DAY

NO. OF
PATIENTS
(%)
(N=493)
51 (10.3)

TWICE A DAY
THRICE A DAY
NA
ONCE A DAY

1 (0.2)
1 (02)
4 (0.8)
2 (0.4)

ONCE A DAY

4 (0.8)

IRON HYDROXIDE+FOLIC
ACID+VIT B12
25MG+500MCG+5MCG
VIT C/ FOLIC ACID+FERROUS
FUMERATE+VITB12
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IRON+FOLIC ACID+ZINC
SULPHATE
100MG+1.5MG+22.5MG

ONCE A DAY

37 (7.5)

NA

4 (0.81)

FERROUS ASCORBATE+FOLIC
ACID
100MG+1.5MG
FERROUS FUMERATE+FOLIC
ACID
152MG+1.5MG
FERROUS FUMERATE+FOLIC
ACID+ZINC SULPHATE
100MG+1500MCG+61.8MG
CYANOCOBALAMIN+ELEMENTA
L COPPER+ELEMENTAL
MANGANESE +FERROUS
AMMONIUM CITRATE +FOLIC
ACID
7.5MCG+3MCG+30MCG+160MG+0
.5MG
IRON+FOLIC
ACID+CYANOCOBALAMIN+NIAC
INAMIDE+PYRIDOXINE.
150MG+1MG+15MCG+2MG+50MG

ONCE A DAY

2 (0.4)

ONCE A DAY

7 (1.4)

NA
ONCE A DAY
NA

3 (0.60)
25 (5.07)
1 (0.2)

ONCE A DAY

13 (2.63)

ONCE A DAY

15 (3.04)

FERROUS FUMARATE
+MULTIVITAMINS
30 MG
ELEMENTAL IR0N+ELEMENTAL
SULPHATE+FOLIC
ACID+METHYCOBALAMIN
60MG+15MG+1MG+500MCG
ELEMENTAL IRON+FERROUS
AMMONIUM CITRATE+FOLIC
ACID+LIVER
FRACTION+PEPTONE
3.95MG+34MG+0.17MG+40MG+20
MG
ELEMENTAL IRON+ L
METHYLFOLATE+MECOBALAMI
N
100MG+300MCG+1500MCG
FERROUS ASCORBATE+ L
METHYL
FOLATE+ZINC+METHYLCOBALA
MIN
100MG+ 500MCG+ 61.8MG

ONCE A DAY

9 (1.82)

ONCE A DAY

1 (0.2))

ONCE A DAY

1 (0.2)

ONCE A DAY

5 (1.01)

ONCE A DAY

1 (0.2)

INJ IRON SUCROSE
100 MG

NA

3(.60)

ONCE A DAY

2 (0.4)
30

ELEMENTAL IRON+ FOLIC
ACID+ VIT B12+ ZINC SULPHATE
152MG+1.5MG+15MCG+15MG
NO ANEMIC DRUG

NA

2 (0.4)

NA

299 (60.6)

Table 9; Pattern of treatment on discharge for adults
ADULT
DRUG

FREQUENCY

VITC+FOLIC ACID+FERROUS
FUMERATE+VITB12
150 MG+1.5MG+350MG+15MCG
FERROUS ASCORBATE+FOLIC ACID
100MG+1.1MG

ONCE A DAY

NO. OF
PATIENTS
(%)
(N=493)
6 (1.21)

ONCE A DAY

57 (11.56)

TWICE A DAY

1 (0.2)

ONCE A DAY

6 (1.21)

NA
ONCE A DAY

1 (0.2)
50 (10.1)

NA
ONCE A DAY

1 (0.2)
1 (0.2)

ONCE A DAY
NA
ONCE A DAY

6 (1.21)
2 (0.4)
12 (2.4)

TWICE A DAY

16 (3.24)

ONCE A DAY

13 (2.63)

ONCE A DAY
TWICE A DAY
THRICE A DAY

2 (0.4)
11 (2.23)
1 (0.2)

IRON HYDROXIDE+FOLIC
ACID+VITB12
25MG+500MCG+5MCG
IRON+FOLIC ACID+ZINC SULPHATE
100MG+1.5MG+22.5MG
FERROUS ASCORBATE+FOLIC ACID
100MG+1.5MG
FERROUS FUMERATE+FOLIC ACID
152MG+1.5MG
FERROUS FUMERATE/FOLIC
ACID/ZINC SULPHATE
100MG+1500MCG+61.8MG
CYANOCOBALAMIN+ELEMENTAL
COPPER+ELEMENTAL MANGANESE
+FERROUS AMMONIUM CITRATE
+FOLIC ACID
7.5MCG+3MCG+30MCG+160MG+0.5M
G
IRON+FOLIC
ACID+CYANOCOBALAMIN+NIACINA
MIDE+PYRIDOXINE
150MG+1MG+15MCG+2MG+50MG
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5. Discussion
This study was conducted in a tertiary health care hospital in South India and it was a retrospective
observational study. IDA patients demographics, risk factors, clinical manifestations and treatment pattern
during stay and on discharge were assessed. A total of 894 patients’ data (out of which 401 (44.8%) were
pediatrics and 493 (55.1) were adults) diagnosed with IDA in the year 2017 were included for evaluation.
In this study out of 995 patients, 894 were diagnosed with Iron Deficiency anemia, 101 patients were
diagnosed with Megaloblastic anemia and 83 patients were diagnosed with both Megalobalstic and Iron
deficiency anemia. Natarajan et al. stated that out of the various different kinds of anemia Iron deficiency
anemia (IDA) is thought to be the most common cause of anaemia globally [8]
It was found that 493 (55.1%) adult patients and 401 (44.9%) pediatric patients had anemia among 894
patients.
In our study it was observed that 160 (40.9%) were female and in adults it was found that the female gender
was the highest distributed risk factor where 276 patients (55.9%) patients were female, which was similar
to the the study by Nataranjan et al. which stated that majority of the patients who suffer from anemia are
female (71%) and are usually more than 15 years of age. This could be attributed to the low nutrition intake
in the females and menstrual blood loss that occurs every month. [8]
We observed 219 (54.6%) pediatric patients were below 2 years of age, which concurrent with the study by
A Zhao et al. in a South Asian country Burma where the result stated that the one of the predictors of anemia
are young age (less than 5 years old ) (P < 0.001) and that there is a high prevalence of anemia in children.
[12]

In adults, age was a risk factor for 128 (25.9%) patients. Although age above 60 years was not a highly

distributed risk factor in adults, according to a study in 2019 by Duman T et al. etiology and causes of
anemia should be carefully investigated in subjects with advanced age and it should be kept in mind that
B12 deficiency and comorbidities were more common in elderly men. .[18]
Our study showed 19 (4.7%) pediatric females were of the child bearing age and 188 (38.1%) adults women
were found to be of the child bearing age. Whereas in a study conducted by Ansari et al. it was found that
out of 200 non-pregnant women 89 (44.5%) patients had IDA. [22]
It was found that 13 (2.6%) adult women were pregnant who had IDA. Many literatures stated that
menstruating women, adolescents and pregnant women are the most risk of developing IDA [13] and apart
from the importance of prophylaxis of IDA in pregnant women, oral and IV preparations are the best
treatment option for IDA. [23]
Only 4 (0.8%) out of 493 adult patients had an occupation which is a risk factor to develop anemia because
of worm infestation (farmer and fisherman). Hookworm infections remain a major cause of morbidity in the
developing world. Prevalence is highest in agricultural areas, where use of waste water for irrigation and
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poor hygiene increases infection rates among farmers. Infections present with gastrointestinal symptoms and
chronic anaemia, and there are usually no signs of overt blood loss. [31]
We observed 109 (26.1%) pediatric patients were vegetarians and 34 (8.4%) were non vegetarians. In adult
patients 71 (14.3%) were vegetarians and 180 (36.4%) were non vegetarians, also the data of diet habits of
many of the patients was not available. So, we found that there is no significant difference in prevelance of
IDA in vegetarians or non-vegetarians which is according to the study conducted by Craig W which
concluded that the iron stores of vegetarians may be reduced but the incidence of iron-deficiency anemia in
vegetarians is not significantly different from that in non-vegetarians [32]
Study found 348 (86.7%) pediatric patients were from a rural area and 423 (85.8%) adult patients were
from a rural area. Many patients from the rural area were lower income group. Low socio economic group
people have higher chances of developing anemia than that of the people in a better socio-economic group.
[13]

Passive smoking is known to unfavourably affect pregnancy, childbirth and infants. It causes RBC
metabolism causing anemia in children. [24] In our study we observed that only small group of population
with smoker and alcoholics, that is 18 (3.6%) adult patients were smokers and 29 (5.8%) adult patients
consumed alcohol. In a study by Ioannou GN et al. it was found that consumption of any form of alcohol
was associated with 40% reduced risk of iron deficiency anemia. [25]
We observed only 2 (0.5%) pediatric patients had a history of GI bleeding, 10 (2%) adult patients had GI
bleeding, 42 (8.5%) adult patients had a history of blood loss and 11 (2.2%) adult patients had hemorrhoids.
Many literature proved that a major amount of Iron is lost through blood loss. [26] and Chronic
gastrointestinal bleeding is the most common cause of iron deficiency anemia (IDA) in the general
population. [28]
A lot of drugs are also associated with increased risk of anemia including Azathioprine, primidone, cytabine,
vinblastin, tetracycline, etc. [13] whereas in our study we observed only 1 (0.2%) pediatric patients was
reported with the usage of methotrexate and 5 (1%) adult patients were reported with the usage of
Sulfasalazine, Methotrexate and Corticosteroids.
In this study pallor was present in majority of the population in adults (242-49.08%) and pediatrics (16641.39%). In a study conducted by Stoltzfus R et al stated that pallor is a simple way to detect anemia, but
more data are needed for its accuracy to assess severity. [30]
On evaluation of clinical manifestation we observed 12 (2.9%) pediatric patients felt fatigued, 9 (2.24%)
patients were weak, 8 (1.9%) patients had shortness of breath, 4 (0.9%) patients were irritable, 3 (0.7%)
patients were dizzy, 1 (0.2%) patient had palpitation, 1 (0.2%) patient had chest pain and 1 (0.2%) patient
had tachycardia.
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Whereas in adult patients 96 (19.47%) patients felt fatigued ,80 (16.2%) patients had shortness of breath, 52
(10.54%) patients were weak, 24 (4.86%) patient had chest pain, 10 (2.01%) patients had decreased
exercise tolerance, 5 (1.01%) patient had palpitation, 5 (1.01%) patients had tingling, 4 (0.81%) patients
were irritable, 3 (0.6%) patients were dizzy, 2 (0.4%) patients had vertigo and 1 (0.2%) patient had
tachycardia
According to Dipiro J et al. the common clinical manifestations in anemia included chest pain, fatigue,
dizziness, irritability, weakness, palpitations, vertigo, tingling, shortness of breath, decreased exercise
tolerance, tachycardia and pallor. [13] It is not required that the patients show all the symptoms for the
diagnosis of IDA, physicans diagnose and treat the anemia based on some of the symptoms and with the
help of laboratory values.
In a retrospective observational study with a sample size of 100, conducted in the Medical Records
Department, Pondicherry Institute of Medical Sciences (PIMS) the patients with IDA had severe IDA
(58%), followed by moderate IDA (36%) [8] where as in our study we found in pediatrics the severity was
moderate in [ (269 (67.1%)], followed by mild in 19.2% and then severe in (7.7%) patients and in adults the
severity was moderate in 49.3%, followed by severe (33.9%) and mild (12.4%).
Out of 401 pediatric patients 121 (30.1%) patients received treatment during hospital stay and out of 493
adult patients 199 (40.3%) patients received treatment. A varied array of interventions exist for the treatment
of IDA involving dietary interventions, fortification of foods with iron and iron supplements can be used for
the treatment of Iron Deficiency Anemia. Once or twice weekly dose of iron in school going children, non
pregnant women and adolescents is recommended whereas for infants (6-24 months) of age require a much
higher intake of iron as they are growing rapidly.[8]
For IDA, in a study by Ahmad et al. it is found that low ferritin levels are equally frequent among children
with or without anemia.[15] And for treatment, a study by Okam et al. stated that oral iron replacement is an
important line for therapy. But it is often poorly tolerated or ineffective. [16] There is a high physiological
requirement of iron in pregnancy which is difficult to meet with most diets. Therefore, iron supplementation
is given to pregnant women in all contexts. supplementation should also continue into the postpartum period
to provide adequate iron stores to women. [14] In this study a regular dose of iron was provided to the
patients with low iron, but iron treatment was not given to all patients. In this study the mean haemoglobin
value for adults and pediatrics did not change drastically even after treatment was provided. Although the
treatment is simple and effective, there is still a high prevalence of Iron Deficiency Anemia the reason
maybe being non-compliance of the patients or due to ineffective or incomplete treatment by the physicians.
[8]
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IDA is more common is South Asian countries like India. Zlotkin et al. states that IDA is associated with
impaired psychomotor development in childhood and there is a major need of new sustainable strategies to
control IDA in children which include promotion of healthy food habits along with improving the nutritional
value of these foods by using complementary supplements. [17]
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LIMITATIONS
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6. LIMITATIONS
● Since this is a retrospective study design, a lot of data was missing or not recorded.
● For a few patients CBC values were not recorded during follow up.
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7. CONCLUSION
Though anemia is a treatable disease it is still highly prevalent around the world. An observational
retrospective study was carried out in a tertiary care hospital with a sample size of 995 who were admitted in
Kasturba Hospital, Manipal in the year 2017.
It was found that there were many more cases of IDA than Megaloblastic anemia and IDA was highly
distributed in adults than in pediatrics. Young adults were the highly affected population in our study.
Among risk factors, female gender was the highly distributed risk factor in adults and age below 2 years was
the highly distributed risk factor in pediatrics. Pallor was commonly observe clinical manifestation in both
the age groups followed by fatigue.
On assessment of severity of anemia based on WHO scale, in pediatrics we found majority of them had mild
followed by moderate and then severe form of anemia. In adults the moderate, severity followed by severe
and then mild form of anemia
It was observed that after the treatment during stay and discharge the outcome of disease in both age groups
did not improve drastically.
This study concluded that it helps in identifying the various risk factor and clinical manifestations of Iron
Deficiency anemia which will in turn help in prevention of the disease by early assessment of the disease
based on these factors. It also gives us an idea of the changes to be made in treatment pattern and//or to provide
counselling to patients regarding adherence to medication and food rich in iron so that the outcome of the
disease was improved.
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FUTURE DIRECTIONS
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8. FUTURE DIRECTIONS:
● A prospective study on comparison between different treatment regimens would yield better result.
● A similar study should be conducted regionally and nationally to yield results at a larger scale.
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Introduction
Folic acid and cobalamin are B-group vitamins that play an essential role in many cellular processes.
Deficiency in one or both of these vitamins causes megaloblastic anaemia, a disease characterized by the
presence of megaloblasts. Treatment generally involves supplementation of VitB12 and folic acid. Generally
a proper diet is very important along with supplementation.
Objectives
To assess the various the pattern, risk factors, and treatment of Megaloblastic anemia (MA) in paediatric and
adult population in tertiary care hospital in South India,

Methodology
A retrospective observational study was conducted in tertiary care hospital after obtaining the approval of the
ethical committee. Data of 184 MA patients who are admitted as MA in 2017 were collected from their files
and recorded in the CRF which included demographic details, their diet and lifestyle, any medical or
medication history, the type of anemia, it’s severity, the treatment and outcome. SPSS version 20 was used to
analyse the data.

Results
The sample size was taken as 184 patients which included 23(12.5%) paediartic and 161(87.5%) adult patient.
Study shown that the number of male patients are more than female(1.55: 1). The highest risk factor in adult
was gender as 63(39.13%) female patients. In-case of paediatric it was found to be age of less than 2
years(39.1%) .Pallor was found to be the most common clinical manifestation in both the population. Out of
23 paediatric patients 14(60.9%) patient patients had pallor and 109 (69%) adult patients had pallor. 62.1%
of the adult population had severe MA,whereas it was 39.1% in paediatric. The most common cause for MA
was found to be deficiency in VitB12.

Conclusion
Study concluded that the result will help us to understand the various preventable risk factor for MA, common
clinical manifestions of disease, food habits which causes MA and the treatment pattern followed for
improvement of the condition. Thus this epidemiological data will helpful for healthcare professionals.
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1. Introduction
Megaloblastic anemia is the condition in which there is presence of macrocytic red blood cells(RBCs) and
there is distinct changes in morphology in the precursors RBC. The deficiency in Vit.B12 & folic acid,
which plays an important role in many cellular process is the main reason for megaloblastic anemia. The
presence of megaloblasts is a characteristic feature of megaloblastic anemia. When asynchronous mutation
occurs between the nucleus and the cytoplasm it results in inhibition of DNA synthesis which results in the
formation of megaloblast. Wide range of malabsorption i.e severe to mild of Vit.B12 can occur depending
on the absorption of VitB12 in the gastric and ileal phase.
Vegetarian people are at a higher risk in case of nutritional deficiency of VitB12. Maternal deficiency of
VitB12 is the reason of VitB12 deficiency in the infants as the content of B12 in the mother’s milk is lower.
Some disease condition such as Giardia infection can cause malabsorption of folate. H.pylori infection
causes malabsorption of VitB12 in adults. Some drug therapies such as Trimethoprim, Methotrexate,
pyrimethamine , metformin[13] which can lead to Megaloblastic anemia.[1]
Vit B12 deficiency affects around 6% in person aged less than 60 years and 20% of the people who are older
than 60 years in the United States and in England. 40% of people in South American countries are affected.
In Kenya 70% of the school children are affected. 80% of children and 70% adults are affected in India.[2]
To treat cobalamin deficiency oral cobalamin is initiated at 1-2 mg daily for one-two weeks, followed by
1mg daily. A common parental therapy 1000mcg daily for one week, then once a week for one month, and
then monthly.
Oral folate 1mg daily for 4 months and 5mg in case of malabsorption is used to treat folic acid deficiency.[3]

NEED FOR THE STUDY
As seen in a study by Khandari U, et al. showed that out of total 120 patient’s data 65% had cobalamin
deficiency, 12% had both cobalamin and folate deficiency and 6% had folate deficiency. The female patients
suffering from megaloblastic anemia was 71%. [4]
Alcohol can be a secondary reason for deficiency of VitB12 although a good nutrition can prevent
deficiency of VitB12. Alcohol acts as a direct toxic on the bone marrow. A study done by Edward
R.Eichner, et al showed in 65 alcoholic patient 40% of the patients developed megaloblastic erythropoiesis
secondary to folic acid deficiency.[5] In a study done by Tungtrongchitr R, et al. in a military unit in Taiwan
involving 123 male smokers and 63 nonsmokers it showed lower level of haemoglobin in smokers. 16.3% of
the smokers were anemic and only 3% of the non-smoker were anemic. The folate levels were found to be
lowered in the smokers.[6]
9

A cross sectional-study done by Hiren P Pandya and Asit Patil showed that out of 50 patients 10 patients
were on mixed diet 40 patients were lacto vegetarian and 13 people were alcoholic i.e. 26% .[7]
A cross-sectional study done by Praphull Deepankar et.al , showed that out of 97 patients fatigueness was
present in 92% of the patient , 59% showed exertional dyspnea, 19% showed palpitation and pallor was seen
in 96% of the patient. [8]
This study is focused on the association of various risk factors associated with megaloblastic anemia like
smoking ,alcoholism ,vegetarian diet. Also demographic details of the patient were assessed to obtain any
link between them and megaloblastic anemia. Any underlying chronic disease were also checked for. The
type ,treatment pattern and risk factors, severity both in adult and pediatric population were studied in south
Indian population .
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2. RESEARCH AIMS AND OBJECTIVES :
AIM: To assess the pattern, risk factors and treatment of Megaloblastic anemia in adult and paediatric
population in a tertiary care hospital in south India.
OBJECTIVE
● To assess the demographic and clinical characteristics of patients.
● To study the distribution pattern and various risk factors affecting anemia in adult and paediatric
population.
● To study the treatment pattern and its outcome
● To find the severity of MA and the type of MA.
● To compare various study parameters in adult and paediatric population.

12

METHODOLOGY

13

3. METHODOLOGY
1. Study site :
This study was performed in the medicine and paediatric department in a tertiary care hospital.
2. Study design :
This was a Retrospective observational study.
3. Study population :
All patients who were admitted in the hospital due to Megaloblastic anemia during Jan 2017- Dec 2017,
with the following inclusion and exclusion criteria were included in the study
•

Inclusion criteria :

All in-patients with final diagnosis of megaloblastic anemia admitted in a tertiary care hospital, Manipal.
•

Exclusion criteria:

Incomplete medical records and patients with other types of anemia.
4. Sample size :
The sample size was 181(107 MA+ 74 IDA+MA(mixed)) i.e. all the patients admitted during January 2017Dec 2017.
5. Ethical clearance :
Ethical clearance has been obtained from KH Institutional Ethics Committee, Ref Number: 471/2018
6. Sources of data collection :
a. Patients record which includes
v Reports of diagnostic and interventional procedures
v Progress sheets
v Laboratory investigation results
v Discharge summary
v Past history notes
b. Daily admission list kept at medical record department.
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7. Materials used :
CASE REPORT FORM(CRF) (APPENDIX-2)
CRF includes hospital number, admission and discharge date, demography of the patients, duration of
treatment, complaints on admission, medical and medication history, surgery history, risk factors such as
smoking and alcoholism, the diet of the patient, any recent bleeding event, clinical manifestations if any
present, the type of anemia and it’s severity, the treatment pattern and it’s outcome, discharge summary,
lab data (appendix-2).

8. Operation Modality :
Study was done in the medicine and paediatric department of a tertiary care hospital in south India. The
sample size was 181 and it included all the patients who were admitted between the time period of Jan
2017- Dec 2017. The data of the patient was recorded in the CRF which included the various risk factor
the lab values, treatment pattern and it’s outcome. The data was then analysed in SPSS version 20.
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9. Collection of Data:
The medical records of all IDA patients were reviewed and the details of the patient were entered in
a case record form. Demographic details like age, gender, occupation and social history were noted.
Information regarding the presence of any Risk factors or chronic illness, pre-hospitalisation period
and type of admission were retrieved from the files on a structured CRF.
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10.Data Analysis :
The obtained data from the medical records of patients with MA were analysed for various
parameters like demographic data, gender ratio, risk factor distribution, clinical manifestation,
prescription pattern, discharge medications, laboratory values, outcomes and severity for pediatrics
(age below 18 years) and adults (age above 18 years) etc using SPSS 20. The results of pediatrics
and adults were compared and represented as descriptive statistics.
The various risk factors for MA were assessed as follows:
The various risk factors considered in this study were age, sex of the patient, previous disease
and medication, any chronic disease if present. Any addiction to alcoholism and smoking
were also taken as risk factors. History of blood loss, history of taking aspirin, diet of the
patient, worm infestation, haemorrhoids, nose bleeding and post-partum haemorrhage if any
present.[23]
The various clinical manifestations for MA were as follows:
Chest Pain, Pallor, Fatigue, Dizziness, Irritability, Weakness, Palpitations, vertigo, Tingling,
Shortness of breath, Decreased exercise tolerance and tachycardia[23]
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4. RESULTS
A total number of 995 patients’ data were collected out of which 811 were diagnosed with IDA, 101 were
diagnosed with Megaloblastic anemia and 83 were diagnosed as IDA and Megaloblastic anemia. In this
study we are focusing on the patients diagnosed with MA.

1.Demographic characteristics of patients with MA
In the year 2017 total of 184 patients were admitted and diagnosed with MA. The distribution
pattern of MA in Gender and various age category is shown in Table 2 respectively.
1.1 Gender wise distribution:
Out of 184 patients the number of paediatric patients were found to be 23(12.5%), in which 13(56.5%)
paediatric patients were male and 10 were female. 161(87.5%) patients were adults. 98(60.9%) patients were
male and 63(39.1%) patients were female.
Table 1; Distribution Pattern of MA according to gender:
CATEGORY
Pediatric
(N-23)

Adult
(N-161)

MALE

13 (56.5)

FEMALE

10 (43.5)

MALE
FEMALE

98 (60.9)
63 (39.1)

1.2 Food Habit wise distribution :
Out of 23 paediatric patients 10 (43.5%) were vegetarians, 3 (13%) were non vegetarians and the data was
not available for 10 (43.5%) patients. And out of 161 paediatric patients 33(20.5%) were vegetarians, 57
(35.4%) were non vegetarians and the data was not available for 71 (44.1%) patients.
Table 2; Food habits of paediatric and adult patients
Category

PEDIATRIC-N=23

NO OF
VEG.PATIENTS(%)
10 (43.5)

FOOD HABITS
NO. OF NON VEG
PATIENTS(%)
3 (13)

ADULT- N=161

33 (20.5)

57(35.4)

NOT MENTIONED(%)
10 (43.5)
71(44.1)
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1.3 Geographical area-wise distribution:
Amongst the 23 pediatric patients 21 (91.3%) were from rural areas and 2(8.7%) were from urban areas.
And out of 161 (85.6%) adult patients 143 (88.8%) were from rural areas and 18(11.2%) were from urban
areas. In case of paediatric patient we saw that 2(8.69%) were from urban and 18(78.26%) were from rural
area.
1.4 Age group-wise distribution
In infancy there were 6(26.08%) patients suffering from MA. In toddler there was two(8.69%) case of MA .
Patient in the early childhood had one case of MA. 14(9.7%) patients in the age category of early
adolescence had MA.
In adults there were 3 age groups; young adults, middle aged adults and geriatrics. In young adults 76 MA
were present, in middle aged adults 60 MA patients were present, in geriatrics.25 MA patients were present
Table 3; Age groupwise distribution :
Age group
Infancy (28 days to 12 months )
Toddler (13months-2 years)
Early Childhood (2-5years)
Middle childhood (6-11 years)
Early Adolescence (12-18 years)
Young adult (19-30 years)
Middle aged adults (31-59 years)
Geriatrics (>60 years)

No. of Patients(%)
N=184
6 (26.08)
2 (8.69)
1 (4.34)
N/A

14(9.7)
76(47.20)
60(37.26)
25(15.52)

2. Distribution of various risk factors in patient with MA

2.1 Distribution of Various Risk Factors in Paediatrics
Age below 2 years and above 60 years is a risk factor for anemia. The various risk factors for
Anemia based on studies include, female gender, occupation, child bearing age, alcohol,
smoking, chronic disease, low absorption in IDA, pregnancy, GI Bleeding, history of blood
loss, history of taking aspirin or NSAID, food habits-veg, place-rural, worm infestation,
haemorrhoids, nose bleeding, postpartum haemorrhage and various drug use. We assessed the
various risk factor prevalence in our patients and found that out of 23 paediatric patients 10
(43.5) patients were female. 9(39.1%) paediatric patients were below 2 years of age.
Amongst 10 females paediatric patients , 3 (13%) paediatric patients were of child bearing
age. 1 (4.3%) patient had a family history. 1(4.3%) had a medical history of fever and gum
bleeding. There was presence of TB in 1(4.3%) as a chronic disease. Valporate was found to
be in the medication history of 1(4.3%) of the patient.
20

2.2 Distribution of Various Risk Factors in adults
In case of the 161 adults patients the risk factors were analysed. 63(39.2%) patients were
female, 39(24.2%) amid the female adult patients were of child bearing age. 12(7.4%) had
HTN 10(6,2%) had T2DM patients had chronic diseases which may or may not have been a
direct risk factor for their anemia. Patients above 60 years of age have risk factor for
developing megaloblastic anemia,30( 18.6%) patients were above 60 years of age. Smoking
and consumption of alcohol was found prevalent in 21(13%) and 23(14.3%) patients in the
adults population. 9 patients were associated with history of blood loss.19 patients had
medical history of disease which are associated with anemia,4(2.5%) patients had VitB12 def
anemia, 2(1.2%) had anemia, HTN was present in 9(5.6%) of the patients and 4(2.5%)
patients had T2DM 3(1.9%) patients were using aspirin and 1 patient(.6%) were on both
aspirin and another NSAID and 2 patients had history of using Metformin. 3 patients(1.9%)
had haemmorhoids and 1 patient had worm-infestation.
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AGE CATEGORY
PEDIATRIC-23

ADULT-161

Fig 1; Distribution of various risk factors in Adults and Pediatrics
.
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3. Presence of Clinical Manifestations
16(69.6%) paediatric patients out of 23 had clinical manifestations present. 7(30.4%) paediatric patients had
no clinical manifestations.

presence of clinical
manifestation in
paediatrics

presence of clinical
manifestation in adults
19%

present

30%

present

not present

70%

not present

81%

Fig 2; Presence of clinical manifestations in pediatrics Fig 3; Presence of clinical manifestations in adults

3. 1Distribution of Clinical Manifestations in Paediatric
The various clinical manifestations associated with anemia are chest pain, fatigue, dizziness, irritability,
weakness, palpitations, vertigo, tingling, shortness of breath, decreased exercise tolerance, tachycardia and
pallor. The clinical manifestations in the paediatric population was assessed. Out of 23 paediatric patients
14(60.9%) patient patients had pallor. Fatigue was found in 6(26.1%) patients. 3 (13%) patient had
weakness. 2 (8.7%) patients felt dizzy. Palpitations and shortness of breath was found each in 1(4.3%)
patient.
3.2 Distribution of Clinical Manifestations in Adults
The clinical manifestation of the adults were found to be the following. 109 (69%) patients had pallor. 73
(45.3%) patients were fatigued. Weakness was present in 24 (14.9%) patients. Dizziness was present in
8(5.0%) patients. 5 (3.1%) patients had a decreased exercise tolerance and tingling sensations each. 4
(2.5%) patients had shortness of breath.
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Figure 4; Distribution of clinical manifestations in pediatrics and adults

4. Severity in Paients with MA

4.1 Severity in Paediatric
Among the 23 the paediatric patients 5 patients(21.7%) were under mild category, 9 patients(39.1) were there
in each moderate and severe category .

SEVERITY IN PEDIATRIC

22%
MILD

39%

MODERATE
SEVERE

39%

Fig 5;Severity in case of paediatric
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4.2 Severity in Adults
Whereas in case of adult patients 7 patients(4.4%) were in mild category, 50(31.6%) were in moderate
category and 97(61.4%) were in severe category.

SEVERITY IN ADULTS
1%
2%
4%

MILD

31%

MODERATE
SEVERE
NORMAL

62%

NA

Fig 6;Severity in case of adult

5.Type : The most common deficiency found in both the population is that of VitB12. 12 patients from
paediatric (52.2%) . Folate acid deficiency was found to be not present in any of the paediatric patient.
98 adult patients (60.9%) and only 7(4.3%) adults had folic acid deficiency. 5(3%) patients in adult population
had deficiency in both vitB12 and folic acid.

Fig 7; Types of anemia in paediatric

Fig 8; Types of anemia in adult
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6. Assessment of Laboratory values
16 laboratory values were recorded on admission for all the patients pediatric and adults a total of
and during follow up although the data was not available for all the patients. In table 5 and table 6
the values for pediatrics and adults are depicted during admission and follow up respectively.

Table 4; List of laboratory parameters with admission and discharge in paediatrics
DURING STAY
HB (g/dl)
MCV (fl)
MCHC(g/dl)
MCH(pg)
PCV (%)
TIBC(mcg/dl)
RBC(cells/µl)
FERRITIN
VITAMIN
B12(pg/ml)
FOLIC ACID
RDW(%)
IRON(mcg/dl)
TRANSFERRIN
INTRINSIC
FACTOR
MMA
HOMOCYSTEINE 0

DURING FOLLOW UP

MEAN ± STANDARD DEVIATION
8.46±2.85
8.95±2.13
93.54±19.29
89.69±24.92mg/dL
32.95±3.30
34.1±6.02
31.11±7.66
32.78±6.96
25.24±8.92
26.51±7.66
182.00±131.73
244.04±84.78
2.54×106±1.28
2.73×106±1.26
31.70±0
0
367.31±625.28
0
39.12 ±48.99
24.51 ±8.93
101.50±78.48
0
0

0
24.33±8.99
88±0
0
0

0

0
0

Table 5; List of laboratory parameters with admission and discharge in adults
DURING STAY
HB (g/dl)
MCV (fl)
MCHC (g/dl)
MCH (pg)
PCV (%)
TIBC (mcg/dl)
RBC(cells/µl)
FERRITIN
VITAMIN
B12(pg/ml)
FOLIC ACID
RDW(%)
IRON(mcg/dl)

DURING FOLLOW UP

MEAN ± STANDARD DEVIATION
6.99 ±2.55
9.33±6.50
89.89 ±27.25
87.74±21.96
32.77 ±5.51
32.24±2.16
31.10 ±11.20
36.37±42.98
22.12 ±10.30
27.12±8.42
311.82 ±112.60
313.5±21.9
2.80×106 ±2.76
3.25×106±1.25
283.70 ±429.19
47.05±30.05
290.04 ±507.10
814.80±890.31
7.10 ±5.93
22.93 ±7.50
71.46±79.626

24.92±7.48
38±0
25

TRANSFERRIN
INTRINSIC
FACTOR
MMA
HOMOCYSTEINE 0

0
0

0
0

0

0
0

7 Treatment pattern during hospital stay and discharge
The treatment pattern during hospital stay and discharge was recorded. Although not all the patients were
given treatment during hospital stay and discharge, the overall frequency of drug use is given in Table 6 and
Table 7 Table 8 Table 9. 18(78.26%) paediatric patients were given treatment during hospital stay ,and 5
patients (21.7%) did not receive any treatment.
In the adult population out of 161 patient ; 147(91.30%) patients received treatment and 15(9.31%). patients
did not receive any treatment.
.

Table 6; drug treatment pattern during hospital stay for paediatric patient
DRUG
T.FOLIC
ACID

INJ VITB12
INJ VIT B12

SYP.VIT B12
T.VIT B
12+FOLIC
ACID
NA

DOSE

PEDIATRIC
FREQUENCY

NO:OF
PATIENTS(%)
3(13.04)

0.5 MG
5 MG

ONCE DAILY
ONCE DAILY

0.3 ML

ONCE
DAILY(1)

1000 mcg

ONCE
DAILY(7)

16 mcg

ONCE
DAILY(1)

166 mcg

ONCE
DAILY(1)

2000 mcg

ONCE
DAILY(2)

500 mcg

ONCE
DAILY(1)

1000 mcg
15 mcg+1mg

NA
ONCE DAILY

1(4.3)
1(4.3)

NA

NA

5(21.7)

13(56.2)
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Table 7; drug treatment pattern during hospital stay for adult patient
ADULT
FREQUENCY
NO: PATIENTS(%)
ONCE DAILY
5 (3.10)

DRUGS
VIT
B12+FOLIC
ACID
VIT B
COMPLEX

DOSE
15 mcg+1mg

NA
ONCE DAILY
15mcg+1mcg TWICE A DAY

2(1.2)

NA

NA

NA

15(9.31)

INJ VIT B12

NA

ONCE DAILY
(2)

1000 mcg

ONCE
DAILY(93)
ONCE
WEEKLY(1)
NA(1)

12 ML

ONCE
DAILY(1)
NA (1)
ONCE
DAILY(24)
THRICE A
DAY(3)
NA(1)
THRICE A DAY
ONCE DAILY
ONCE DAILY

127(75.15)

2000 mcg

4000 Mcg
T.FOLIC ACID
5 MG

12(7.45)

Table 8; paediatric discharge drug treatment pattern
DISCHARGE
MEDICATION
T.FOLIC ACID

DOSE
5 MG

PEDIATRIC
FREQUENCY
ONCE DAILY
ONCE DAILY
ONCE DAILY

NO:PATIENTS(%)
4(17.39)
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VIT B12+ FOLIC
ACID
NA
INJ VIT B12

ONCE WEEKLY
ONCE DAILY
NA
15 mcg + 1 mg
1000 mcg
330 mcg
100 mcg
500 mcg

NA
ONCE DAILY
ONCE DAILY
ONCE WEEKLY
ONCE MONTHLY
ONCE WEEKLY
ONCE WEEKLY

1(4.34)
7(30.43)
11(47.82)

Table 9; Adult discharge drug treatment pattern
DISCHARGE
MEDICATION
T.FOLIC ACID

VIT B12+ FOLIC ACID

FREQUENCY
5 MG
NA
NA
15 mcg + 1 mg

INJ VIT B12

NA
1000mcg

330mcg

2000 mcg
2 ML
500 mcg
5ML
4000 mcg

ADULT
DURATION
ONCE DAILY
ONCE DAILY
ONCE WEEKLY
ONCE DAILY
ONCE DAILY
NA
ONCE DAILY
ONCE DAILY
ONCE DAILY
ONCE DAILY
NA
ONCE DAILY
NA(5)
ONCE DAILY(18)
ONCE WEEKLY(38)
ONCE MONTHLY(1)
NA(3)
ONCE DAILY(5)
ONCE WEEKLY(8)
ONCE DAILY(6)
ONCE WEEKLY(9)
ONCE IN TWO DAYS(1)
NA(1)
ONCE WEEKLY(2)
ONCE DAILY(1)
ONCE DAILY(1)
ONCE WEEKLY(1)
ONCE MONTHLY(1)

NO OF PATIENTS(%)
19(11.80)

10(6.21)

1O3(63.97%)

8. OUTCOME
The treatment outcome was assessed in both the population. Out of 23 pediatric patients, 11 (47.8%) patients’
laboratory values and condition improved after treatment, and data was not available for 12 (52.2%) patients.
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Out of 161 adult patients, 109 (67.7%) patients’ laboratory values and condition improved after treatment, 11
(6.8%) patients’ values did not improve and data was not available for 41 (25.5%) patients.

OUTCOME
no:of patients

200
150

41
11

100

109

50
0

12
0
11
PEDIATRIC-23

ADULT -161

age category
IMPROVED

NOT IMPROVED

NA

Figure 9; Outcome of treatment
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7. DISCUSSION
The present study was conducted in the paediatric and medicine unit of a tertiary Health care hospital in
south India and it was a retrospective observational study. Data from 181 MA patients’ files were collected
who were admitted in the year 2017. Out of which 161(87.97%) were adults and 23(12.56%) were paediatric
In the case of paediatric population 13 (56.5%) were males and 10 (43.5%) were female. In the adult
population, the number of male patient was found to be 98((60.9%) and the number of females
were 63(39.1%) Hence, the ratio of male:female is 1.55:1was found in adults. Similar results observed by
Praphull Deepankar et.al, showed that the ratio of male to female is 2.6:1[8]i.e. men are affected by MA more
than woman.
10 (43.5%) pediatric patients were vegetarian and 3 (13%) patients were non vegetarians and data of food
habits was not available for 10(43.5%)patients. Amongst adult patients 33 (20.9%) patients were
vegetarian and 55 were non-vegetarian (55%) and data was not available for 71 pateints (44.1%) where as in
the study by Deepankar, et al. where63%of the population were non-vegetarian and 36 (37%) people were
on vegetarian diet[8] and a cross sectional-study done by Hiren P Pandya and Asit Patil showed that out of 50
Megaloblastic Anaemic patients, 10 patients were on mixed diet and 40 patients were lacto vegetarian.[9]
Incomplete data of not knowing how often a non-vegetarian diet is consumed by a non-vegetarian patient
and missing data for a lot of patients megaloblastic anemia could not be positively correlated with the diet
pattern in our study. A study done by Britt et.al showed that 96% of patients with VitB12 deficiency, 60%
with mixed anemia and 100% with folic acid deficiency were vegetarians.[25] Chanarin et al. studied 138
Indian patients with MA in the year 1885 and their study all were vegetarians.[26]
21 (91.3%) pediatric patients were from rural areas and 2( 8.7%) were from urban areas.And out of 161
(85.6%) adult patients 143 (88.8%) were from rural areas and 18 (11.2%) were from urban areas. It shows
majority of MA patients are from rural are in our study.
63 patients in adults were female which was seen to be the highest risk factor .39(24.2%) female adult
patients were of child bearing age, which was highest observed second highest risk factor in this study. In
paediatrics it was seen that 10 female patient was present which is the highest risk factor in this study in the
paediatric population..
It was observed that in the paediatric group a total of 8(34.70%)children who are below the age of two years
were found to have Megaloblastic Anemia which correlates with the fact that children below the age of 2
years are under the risk of developing megaloblastic anemia[20]mainly in the tropical and subtropical
countries. The main reason being that these children are breast-fed by mothers who are malnourished and
have lower level of cobalamin and folate in their blood.[21]
Current study found 25 (15.52%) patients were diagnosed with Megaloblastic Anemia respectively in the
geriatric population which was a risk factor. In UK and USA nearly 6% of the people under 60 years
and 20% of the people above 60 years were affected with VitB12.[22].
We observed 60(37.26%) patients were detected with Megaloblastic Anemia in the middle aged adults. 76
( 47.20%) patients with Megaloblastic Anemia were found in the young adults. This relates to the study
done by Deepankar et al. where the highest incidence of MA was found in the age-group of 22- 40 years[8]
It was found that in adults, 11 (7%) patients had hypertension, 6 (3.8%) had Type2Diabetes Mellitus
, 1(0.62%)patient also had history of Chronic liver disease. These diseases can cause damage to the kidney
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which can lead to anemia.Deficiency of folic acid and/or VitB12 may be exacerbated in patients with
chronic liver disease, who have a the lack of Vit B12 and/ folic acid in their diet.[10] .
Our study showed that 2 (1.3%) patients had history of taking metformin and 3 (1.9%) patients were using
aspirin and 1(6%) patient were on both aspirin and NSAID. These drug interferes the synthesis of DNA like
antimetabolites and alkylating agent can induce megaloblastic anemia. People who have dietary deficiency
of folate are more prone to developing megaloblastic anemia in case they use drugs such as Trimethoprin.
Drugs like aspirin, anticonvulsants (phenytoin), antibiotics like sulfasalazine all are associated with folic
acid deficiency by reducing the transport of folate. Cobalamin deficiency can occur in persons with Type 2
Diabetes Mellitus and chronic use of metformin in large amounts. [13]Whereas Proton pump inhibitors can
reduce cobalamin deficiency [11] [12]
Alcohol is said to be a secondary reason for deficiency of VitB12 although a good nutrition prevents
deficiency of VitB12 in alcoholics. [23]Our study showed that 22 (13.9%) adults were alcoholics. Alcohol
acts as a direct toxic on the bone marrow. A study done by Edward R.Eichner, et al showed among 65
alcoholic patient 40% of the patients developed megaloblastic erythropoiesis secondary to folic acid
deficiency. [5]
It was found that 20 (12.7%) adults were smokers. A study done by Tungtrongchitr R, et al. in a military unit
in Taiwan involving 123 male smokers and 63 non-smokers showed lower level of haemoglobin in smokers.
16.3 % of the smokers were anaemic and only 3% of the non-smoker were anaemic. The folate levels were
found to be lowered in the smokers.[6][7]
The symptoms corresponding to anemia were fatigue, pallor which is the paleness of the skin, dizziness or
light headedness an irregular heartbeat or tachycardia which are common in anemia, may develop it at some
point.[24]
It was observed in our study that the highest clinical manifestation was pallor. Also 14 (60.9%) pediatric 73
(26.1%) adult patients complained of fatigue. Weakness and dizziness were present in 24 (14.9%) pediatric
and 8 (5%) adult patients. 5 (3.1%) adult patients had a decreased exercise tolerance and/or tingling
sensations. 4 (2.5%) adult patients had shortness of breath. In a study done by Deepankar etal. 92-96%
dyspnea and palpitation were the presenting complaints in the patients.[8] It shows different patients shows
different clinical manifestation of MA or anemia.

On evaluation of category of MA, the most common deficiency found in both the paediatric and adult was
of VitB12. That is 12 (52.2%) paediatric and 95 (60.1%) adult patients had VitB12 deficiency. Only 7
(4.4%) adults had folic acid deficiency. 5(3.1%)patients in adult population had deficiency in both vitB12
and/or folic acid and data was not available for 51(31.7%) of the patient. Khandari U, et al. showed that out
of total 120 patient’s data 65% had cobalamin deficiency, 12% had both cobalamin and folate deficiency
and 6% had folate deficiency.
On assessing the severity of anemia, we found 7 patients (4.4%) were in the mild category, 50 (31.6%) were
in moderate category and 97 (61.4%) patients were in severe categoty in the adult population. Among the 23
the paediatric patients 5 patients (21.7%) were under mild category, 9 patients (39.1) were there in each
moderate and severe category. A study done by Pandeya et al. showed that 94% of the adult patients were
presented with moderate to severe anemia.[9]
Out of 23 pediatric patients, 11 (47.8%) patients’ laboratory values and condition improved after treatment,
and data was not available for 12 (52.2%) patients. In adult patients, 109 (67.7%) patients’ laboratory values
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and condition improved after treatment, 11 (6.8%) patients’ values did not improve and data was not
available for 41 (25.5%) patients.
18(78.26%) paediatric and 147 (91.30%) adult patients received treatment. Intramuscular injections
containing crystalline VitB12 have been used since long to treat VitB12 deficiency. The duration of the
treatment was for 8 weeks, and the dose was 1mg or 1000mcg. After that 1mg is given once monthly the
whole life. [14][15] According to Cochrane review of 2005 oral dosage of VitB12 of 1-2 mg daily for 3-4
months showed better results of improvement of level of serum vitB12 compared to those who had received
intramuscular injection of Vit B12.[16]Due to the lower cost and better results oral vitB12 remains a justified
choice.
In megaloblastic anemia there was development of reticulocytes and the haematocrit normalized .[17]VitB12
is a water soluble vitamin so doses 1000 times the dietary allowances is considered safe [18]. The
biologically active form of the vitamins and folic acid used as synthetic supplements or as fortified food and
for treatment of folate . It is absorbed from the proximal small intestine and the rest half is found in the liver.
According to a study by Mckillop et.al, the amount of natural folates in food is influenced by the cooking
process as a variable degradation can take place. The bioavailability of food folate is lowered to half than
folic acid.[19]
Since 1940 folic acid, a water soluble vitamin used to treat microcytic anemia with neurological disorder.
The red blood cell folate level plus microcytosis and/or megaloblastic anemia was best way to diagnose
folate deficiency. Folic acid not only helped to treat it’s deficiency but also a daily dose of 400mcg helped in
reducing the neural defects in women by 45%.According to British National Formulary Folate deficient
megaloblastic anaemia (due to dietary insufficiency, pregnancy or antiepileptics): 5 mg of folic acid daily
was taken for 4 months, except in pregnancy where it was continued until term, and up to 15 mg daily for 4
months was suggested in malabsorptive states. [20]
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LIMITATIONS
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8. LIMITATIONS
● Since this is a retrospective study design, a lot of data was missing or not recorded.
● For a few patients CBC values were not recorded during follow up.
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9. CONCLUSION

Megaloblastic anemia is a disease mainly caused due to deficiency of Vit B12 and folic acid. It can be treated
easily with a proper diet and nutritional supplements. . Male patients are having more megaloblastic anemia.
Age less than 2 years and above 60 years were having anemia found in more numbers .Alcoholism and
smoking were found to be present only in the adult population. 23(14.3%) people were found to be alcoholics
and 21(13%) of the people were smoker. Pallor is the most common clinical manifestation in majority of the
patients. The most common deficiency found in both the population is that of VitB12. Folic acid deficiency
was not present in the paediatric patients. 98 adult patients (60.9%) had Vit B12 deficiency and only 7(4.3%)
adults had folic acid deficiency. 5 patients in adult population had deficiency in both vitB12 and folic acid.
Majority of MA patients of both pediatric and adults received treatment according to standard therapy
mentioned in the literature. Also majority patients imoroved after the treatment
Study concluded that the result will help us to understand the various preventable risk factor for MA, , common
clinicalmanifestions of disease, food habits which causes MA and the treatment pattern followed for
improvement of the condition. Thus this epidemiological data will helpful for healthcare professionals

..
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10.

FUTURE DIRECTIONS:

● A prospective study on comparison between different treatment regimens would yield better result.
● A similar study should be conducted regionally and nationally to yield results at a larger scale.
● Taking a control group to find out the association of risk factor.
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